nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—SELE—multiple sclerosis	0.275	0.512	CbGaD
Carvedilol—VCAM1—multiple sclerosis	0.262	0.488	CbGaD
Carvedilol—XDH—Azathioprine—multiple sclerosis	0.0792	0.331	CbGbCtD
Carvedilol—CYP2E1—Fingolimod—multiple sclerosis	0.0298	0.124	CbGbCtD
Carvedilol—CYP2D6—Fingolimod—multiple sclerosis	0.0142	0.0592	CbGbCtD
Carvedilol—CYP2E1—Mitoxantrone—multiple sclerosis	0.014	0.0584	CbGbCtD
Carvedilol—ABCB1—Methylprednisolone—multiple sclerosis	0.0097	0.0405	CbGbCtD
Carvedilol—CYP1A1—Dexamethasone—multiple sclerosis	0.00939	0.0392	CbGbCtD
Carvedilol—CYP3A4—Fingolimod—multiple sclerosis	0.00902	0.0377	CbGbCtD
Carvedilol—CYP2E1—Dexamethasone—multiple sclerosis	0.00725	0.0303	CbGbCtD
Carvedilol—ABCB1—Mitoxantrone—multiple sclerosis	0.00707	0.0295	CbGbCtD
Carvedilol—ABCB1—Betamethasone—multiple sclerosis	0.00631	0.0263	CbGbCtD
Carvedilol—ABCB1—Prednisolone—multiple sclerosis	0.00622	0.026	CbGbCtD
Carvedilol—ABCB1—Prednisone—multiple sclerosis	0.00588	0.0245	CbGbCtD
Carvedilol—CYP3A4—Methylprednisolone—multiple sclerosis	0.00581	0.0243	CbGbCtD
Carvedilol—CYP3A4—Triamcinolone—multiple sclerosis	0.0044	0.0184	CbGbCtD
Carvedilol—CYP3A4—Mitoxantrone—multiple sclerosis	0.00424	0.0177	CbGbCtD
Carvedilol—CYP2C9—Dexamethasone—multiple sclerosis	0.00378	0.0158	CbGbCtD
Carvedilol—CYP3A4—Betamethasone—multiple sclerosis	0.00378	0.0158	CbGbCtD
Carvedilol—CYP3A4—Prednisolone—multiple sclerosis	0.00373	0.0156	CbGbCtD
Carvedilol—ABCB1—Dexamethasone—multiple sclerosis	0.00367	0.0153	CbGbCtD
Carvedilol—CYP3A4—Prednisone—multiple sclerosis	0.00352	0.0147	CbGbCtD
Carvedilol—CYP2D6—Dexamethasone—multiple sclerosis	0.00346	0.0144	CbGbCtD
Carvedilol—ABCB1—Methotrexate—multiple sclerosis	0.00295	0.0123	CbGbCtD
Carvedilol—HIF1A—nerve—multiple sclerosis	0.00248	0.0589	CbGeAlD
Carvedilol—CYP3A4—Dexamethasone—multiple sclerosis	0.0022	0.00918	CbGbCtD
Carvedilol—VCAM1—retina—multiple sclerosis	0.00107	0.0254	CbGeAlD
Carvedilol—HIF1A—brainstem—multiple sclerosis	0.00106	0.0253	CbGeAlD
Carvedilol—GJA1—brainstem—multiple sclerosis	0.00103	0.0245	CbGeAlD
Carvedilol—HIF1A—retina—multiple sclerosis	0.00103	0.0244	CbGeAlD
Carvedilol—GJA1—retina—multiple sclerosis	0.000995	0.0237	CbGeAlD
Carvedilol—NPPB—nervous system—multiple sclerosis	0.000931	0.0222	CbGeAlD
Carvedilol—HIF1A—Adenosine monophosphate—Cladribine—multiple sclerosis	0.0009	0.299	CbGdCrCtD
Carvedilol—NPPB—central nervous system—multiple sclerosis	0.000897	0.0213	CbGeAlD
Carvedilol—NDUFC2—retina—multiple sclerosis	0.000866	0.0206	CbGeAlD
Carvedilol—SELE—medulla oblongata—multiple sclerosis	0.000837	0.0199	CbGeAlD
Carvedilol—VCAM1—medulla oblongata—multiple sclerosis	0.00077	0.0183	CbGeAlD
Carvedilol—SELE—midbrain—multiple sclerosis	0.000765	0.0182	CbGeAlD
Carvedilol—SELE—spinal cord—multiple sclerosis	0.000747	0.0178	CbGeAlD
Carvedilol—HIF1A—medulla oblongata—multiple sclerosis	0.000741	0.0176	CbGeAlD
Carvedilol—GJA1—medulla oblongata—multiple sclerosis	0.000719	0.0171	CbGeAlD
Carvedilol—NPPB—brain—multiple sclerosis	0.000712	0.0169	CbGeAlD
Carvedilol—VCAM1—midbrain—multiple sclerosis	0.000704	0.0168	CbGeAlD
Carvedilol—ADRA2A—peripheral nervous system—multiple sclerosis	0.000694	0.0165	CbGeAlD
Carvedilol—VCAM1—spinal cord—multiple sclerosis	0.000687	0.0163	CbGeAlD
Carvedilol—HIF1A—midbrain—multiple sclerosis	0.000677	0.0161	CbGeAlD
Carvedilol—HIF1A—spinal cord—multiple sclerosis	0.000661	0.0157	CbGeAlD
Carvedilol—GJA1—midbrain—multiple sclerosis	0.000657	0.0156	CbGeAlD
Carvedilol—GJA1—spinal cord—multiple sclerosis	0.000641	0.0153	CbGeAlD
Carvedilol—SELE—nervous system—multiple sclerosis	0.000629	0.015	CbGeAlD
Carvedilol—NDUFC2—medulla oblongata—multiple sclerosis	0.000626	0.0149	CbGeAlD
Carvedilol—SELE—central nervous system—multiple sclerosis	0.000606	0.0144	CbGeAlD
Carvedilol—SELE—cerebellum—multiple sclerosis	0.000592	0.0141	CbGeAlD
Carvedilol—VCAM1—nervous system—multiple sclerosis	0.000579	0.0138	CbGeAlD
Carvedilol—NDUFC2—midbrain—multiple sclerosis	0.000572	0.0136	CbGeAlD
Carvedilol—NDUFC2—spinal cord—multiple sclerosis	0.000558	0.0133	CbGeAlD
Carvedilol—VCAM1—central nervous system—multiple sclerosis	0.000557	0.0133	CbGeAlD
Carvedilol—HIF1A—nervous system—multiple sclerosis	0.000557	0.0133	CbGeAlD
Carvedilol—GJA1—nervous system—multiple sclerosis	0.00054	0.0129	CbGeAlD
Carvedilol—HIF1A—central nervous system—multiple sclerosis	0.000536	0.0128	CbGeAlD
Carvedilol—HIF1A—cerebellum—multiple sclerosis	0.000524	0.0125	CbGeAlD
Carvedilol—GJA1—central nervous system—multiple sclerosis	0.00052	0.0124	CbGeAlD
Carvedilol—GJA1—cerebellum—multiple sclerosis	0.000508	0.0121	CbGeAlD
Carvedilol—VEGFA—spinal cord—multiple sclerosis	0.000506	0.012	CbGeAlD
Carvedilol—SELE—brain—multiple sclerosis	0.000481	0.0114	CbGeAlD
Carvedilol—NDUFC2—nervous system—multiple sclerosis	0.00047	0.0112	CbGeAlD
Carvedilol—NDUFC2—central nervous system—multiple sclerosis	0.000453	0.0108	CbGeAlD
Carvedilol—NDUFC2—cerebellum—multiple sclerosis	0.000442	0.0105	CbGeAlD
Carvedilol—VCAM1—brain—multiple sclerosis	0.000442	0.0105	CbGeAlD
Carvedilol—HIF1A—brain—multiple sclerosis	0.000426	0.0101	CbGeAlD
Carvedilol—GJA1—brain—multiple sclerosis	0.000413	0.00983	CbGeAlD
Carvedilol—VEGFA—cerebellum—multiple sclerosis	0.000401	0.00955	CbGeAlD
Carvedilol—NDUFC2—brain—multiple sclerosis	0.000359	0.00855	CbGeAlD
Carvedilol—VEGFA—brain—multiple sclerosis	0.000326	0.00776	CbGeAlD
Carvedilol—ADRA1A—brainstem—multiple sclerosis	0.000305	0.00727	CbGeAlD
Carvedilol—ADRA1B—nervous system—multiple sclerosis	0.000285	0.00678	CbGeAlD
Carvedilol—ADRA1D—nervous system—multiple sclerosis	0.000279	0.00663	CbGeAlD
Carvedilol—ADRA1B—central nervous system—multiple sclerosis	0.000274	0.00653	CbGeAlD
Carvedilol—ADRA1D—central nervous system—multiple sclerosis	0.000268	0.00638	CbGeAlD
Carvedilol—ADRA1B—brain—multiple sclerosis	0.000218	0.00518	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Methylprednisolone—multiple sclerosis	0.000215	0.0714	CbGdCrCtD
Carvedilol—ADRA1D—brain—multiple sclerosis	0.000213	0.00507	CbGeAlD
Carvedilol—KCNH2—medulla oblongata—multiple sclerosis	0.000206	0.0049	CbGeAlD
Carvedilol—ADRA2C—medulla oblongata—multiple sclerosis	0.000203	0.00483	CbGeAlD
Carvedilol—ADRB1—nervous system—multiple sclerosis	0.000202	0.00482	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Prednisone—multiple sclerosis	0.000196	0.0652	CbGdCrCtD
Carvedilol—ADRB1—central nervous system—multiple sclerosis	0.000195	0.00464	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Prednisolone—multiple sclerosis	0.000192	0.0636	CbGdCrCtD
Carvedilol—KCNH2—midbrain—multiple sclerosis	0.000188	0.00447	CbGeAlD
Carvedilol—ADRA2C—midbrain—multiple sclerosis	0.000186	0.00441	CbGeAlD
Carvedilol—KCNH2—spinal cord—multiple sclerosis	0.000183	0.00437	CbGeAlD
Carvedilol—ADRA2C—spinal cord—multiple sclerosis	0.000181	0.00431	CbGeAlD
Carvedilol—CYP2D6—brainstem—multiple sclerosis	0.00018	0.00428	CbGeAlD
Carvedilol—ADRA2A—medulla oblongata—multiple sclerosis	0.000162	0.00385	CbGeAlD
Carvedilol—ADRA1A—nervous system—multiple sclerosis	0.00016	0.00381	CbGeAlD
Carvedilol—CYP2E1—medulla oblongata—multiple sclerosis	0.000158	0.00377	CbGeAlD
Carvedilol—ADRB1—brain—multiple sclerosis	0.000155	0.00368	CbGeAlD
Carvedilol—KCNH2—nervous system—multiple sclerosis	0.000155	0.00368	CbGeAlD
Carvedilol—ADRA1A—central nervous system—multiple sclerosis	0.000154	0.00367	CbGeAlD
Carvedilol—ADRA2C—nervous system—multiple sclerosis	0.000153	0.00363	CbGeAlD
Carvedilol—ADRA1A—cerebellum—multiple sclerosis	0.000151	0.00358	CbGeAlD
Carvedilol—KCNH2—central nervous system—multiple sclerosis	0.000149	0.00354	CbGeAlD
Carvedilol—ADRA2A—midbrain—multiple sclerosis	0.000148	0.00352	CbGeAlD
Carvedilol—ADRA2C—central nervous system—multiple sclerosis	0.000147	0.00349	CbGeAlD
Carvedilol—KCNH2—cerebellum—multiple sclerosis	0.000145	0.00346	CbGeAlD
Carvedilol—GJA1—Rimexolone—Methylprednisolone—multiple sclerosis	0.000145	0.0481	CbGdCrCtD
Carvedilol—ADRA2A—spinal cord—multiple sclerosis	0.000144	0.00344	CbGeAlD
Carvedilol—ADRA2C—cerebellum—multiple sclerosis	0.000144	0.00342	CbGeAlD
Carvedilol—GJA1—Rimexolone—Dexamethasone—multiple sclerosis	0.000142	0.0473	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Betamethasone—multiple sclerosis	0.000142	0.0473	CbGdCrCtD
Carvedilol—CYP2E1—spinal cord—multiple sclerosis	0.000141	0.00336	CbGeAlD
Carvedilol—GJA1—Rimexolone—Triamcinolone—multiple sclerosis	0.000139	0.0462	CbGdCrCtD
Carvedilol—PTGS1—spinal cord—multiple sclerosis	0.000136	0.00324	CbGeAlD
Carvedilol—GJA1—Rimexolone—Prednisone—multiple sclerosis	0.000132	0.0439	CbGdCrCtD
Carvedilol—CYP1A1—nervous system—multiple sclerosis	0.000131	0.00311	CbGeAlD
Carvedilol—GJA1—Rimexolone—Prednisolone—multiple sclerosis	0.000129	0.0428	CbGdCrCtD
Carvedilol—CYP1A1—central nervous system—multiple sclerosis	0.000126	0.00299	CbGeAlD
Carvedilol—ABCB1—retina—multiple sclerosis	0.000125	0.00297	CbGeAlD
Carvedilol—ADRA1A—brain—multiple sclerosis	0.000122	0.00291	CbGeAlD
Carvedilol—ADRA2A—nervous system—multiple sclerosis	0.000122	0.0029	CbGeAlD
Carvedilol—CYP2E1—nervous system—multiple sclerosis	0.000119	0.00283	CbGeAlD
Carvedilol—KCNH2—brain—multiple sclerosis	0.000118	0.00281	CbGeAlD
Carvedilol—ADRA2A—central nervous system—multiple sclerosis	0.000117	0.00279	CbGeAlD
Carvedilol—ADRA2C—brain—multiple sclerosis	0.000117	0.00277	CbGeAlD
Carvedilol—PTGS1—nervous system—multiple sclerosis	0.000115	0.00273	CbGeAlD
Carvedilol—CYP2E1—central nervous system—multiple sclerosis	0.000115	0.00273	CbGeAlD
Carvedilol—ADRA2A—cerebellum—multiple sclerosis	0.000115	0.00273	CbGeAlD
Carvedilol—CYP2E1—cerebellum—multiple sclerosis	0.000112	0.00267	CbGeAlD
Carvedilol—PTGS1—central nervous system—multiple sclerosis	0.00011	0.00263	CbGeAlD
Carvedilol—CYP1A1—brain—multiple sclerosis	9.98e-05	0.00237	CbGeAlD
Carvedilol—CYP3A4—nervous system—multiple sclerosis	9.58e-05	0.00228	CbGeAlD
Carvedilol—CYP2D6—nervous system—multiple sclerosis	9.43e-05	0.00224	CbGeAlD
Carvedilol—GJA1—Progesterone—Prednisolone—multiple sclerosis	9.38e-05	0.0311	CbGdCrCtD
Carvedilol—ADRA2A—brain—multiple sclerosis	9.3e-05	0.00221	CbGeAlD
Carvedilol—CYP3A4—central nervous system—multiple sclerosis	9.22e-05	0.00219	CbGeAlD
Carvedilol—CYP2E1—brain—multiple sclerosis	9.1e-05	0.00217	CbGeAlD
Carvedilol—CYP2D6—central nervous system—multiple sclerosis	9.08e-05	0.00216	CbGeAlD
Carvedilol—ABCB1—medulla oblongata—multiple sclerosis	9.02e-05	0.00215	CbGeAlD
Carvedilol—CYP2D6—cerebellum—multiple sclerosis	8.87e-05	0.00211	CbGeAlD
Carvedilol—PTGS1—brain—multiple sclerosis	8.77e-05	0.00209	CbGeAlD
Carvedilol—ABCB1—midbrain—multiple sclerosis	8.25e-05	0.00196	CbGeAlD
Carvedilol—ABCB1—spinal cord—multiple sclerosis	8.05e-05	0.00191	CbGeAlD
Carvedilol—CYP2D6—brain—multiple sclerosis	7.21e-05	0.00171	CbGeAlD
Carvedilol—ABCB1—nervous system—multiple sclerosis	6.78e-05	0.00161	CbGeAlD
Carvedilol—ABCB1—central nervous system—multiple sclerosis	6.53e-05	0.00155	CbGeAlD
Carvedilol—ABCB1—cerebellum—multiple sclerosis	6.38e-05	0.00152	CbGeAlD
Carvedilol—Anaphylactic shock—Methylprednisolone—multiple sclerosis	6.07e-05	0.000671	CcSEcCtD
Carvedilol—Syncope—Dexamethasone—multiple sclerosis	6.06e-05	0.00067	CcSEcCtD
Carvedilol—Syncope—Betamethasone—multiple sclerosis	6.06e-05	0.00067	CcSEcCtD
Carvedilol—Infection—Triamcinolone—multiple sclerosis	6.04e-05	0.000668	CcSEcCtD
Carvedilol—Infection—Methylprednisolone—multiple sclerosis	6.03e-05	0.000666	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—multiple sclerosis	6e-05	0.000664	CcSEcCtD
Carvedilol—Shock—Triamcinolone—multiple sclerosis	5.98e-05	0.000661	CcSEcCtD
Carvedilol—Insomnia—Prednisolone—multiple sclerosis	5.98e-05	0.000661	CcSEcCtD
Carvedilol—Alopecia—Prednisone—multiple sclerosis	5.97e-05	0.000661	CcSEcCtD
Carvedilol—Shock—Methylprednisolone—multiple sclerosis	5.97e-05	0.00066	CcSEcCtD
Carvedilol—Loss of consciousness—Dexamethasone—multiple sclerosis	5.94e-05	0.000657	CcSEcCtD
Carvedilol—Loss of consciousness—Betamethasone—multiple sclerosis	5.94e-05	0.000657	CcSEcCtD
Carvedilol—Hypersensitivity—Mitoxantrone—multiple sclerosis	5.94e-05	0.000656	CcSEcCtD
Carvedilol—Paraesthesia—Prednisolone—multiple sclerosis	5.94e-05	0.000656	CcSEcCtD
Carvedilol—Tachycardia—Triamcinolone—multiple sclerosis	5.93e-05	0.000656	CcSEcCtD
Carvedilol—Nausea—Azathioprine—multiple sclerosis	5.92e-05	0.000655	CcSEcCtD
Carvedilol—Tachycardia—Methylprednisolone—multiple sclerosis	5.92e-05	0.000655	CcSEcCtD
Carvedilol—Skin disorder—Methylprednisolone—multiple sclerosis	5.89e-05	0.000651	CcSEcCtD
Carvedilol—Malnutrition—Prednisone—multiple sclerosis	5.89e-05	0.000651	CcSEcCtD
Carvedilol—Hyperhidrosis—Triamcinolone—multiple sclerosis	5.88e-05	0.00065	CcSEcCtD
Carvedilol—Hyperhidrosis—Methylprednisolone—multiple sclerosis	5.86e-05	0.000648	CcSEcCtD
Carvedilol—Convulsion—Dexamethasone—multiple sclerosis	5.86e-05	0.000648	CcSEcCtD
Carvedilol—Convulsion—Betamethasone—multiple sclerosis	5.86e-05	0.000648	CcSEcCtD
Carvedilol—Hypertension—Dexamethasone—multiple sclerosis	5.83e-05	0.000645	CcSEcCtD
Carvedilol—Hypertension—Betamethasone—multiple sclerosis	5.83e-05	0.000645	CcSEcCtD
Carvedilol—Asthenia—Mitoxantrone—multiple sclerosis	5.78e-05	0.000639	CcSEcCtD
Carvedilol—Myalgia—Betamethasone—multiple sclerosis	5.75e-05	0.000636	CcSEcCtD
Carvedilol—Myalgia—Dexamethasone—multiple sclerosis	5.75e-05	0.000636	CcSEcCtD
Carvedilol—Discomfort—Dexamethasone—multiple sclerosis	5.68e-05	0.000629	CcSEcCtD
Carvedilol—Discomfort—Betamethasone—multiple sclerosis	5.68e-05	0.000629	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—multiple sclerosis	5.68e-05	0.000628	CcSEcCtD
Carvedilol—Hypotension—Methylprednisolone—multiple sclerosis	5.67e-05	0.000627	CcSEcCtD
Carvedilol—Pain—Prednisolone—multiple sclerosis	5.65e-05	0.000625	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—multiple sclerosis	5.65e-05	0.000625	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—multiple sclerosis	5.61e-05	0.00062	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—multiple sclerosis	5.58e-05	0.000617	CcSEcCtD
Carvedilol—Vision blurred—Prednisone—multiple sclerosis	5.55e-05	0.000613	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—multiple sclerosis	5.54e-05	0.000612	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.54e-05	0.000612	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.53e-05	0.000611	CcSEcCtD
Carvedilol—Oedema—Betamethasone—multiple sclerosis	5.52e-05	0.00061	CcSEcCtD
Carvedilol—Anaphylactic shock—Betamethasone—multiple sclerosis	5.52e-05	0.00061	CcSEcCtD
Carvedilol—Anaphylactic shock—Dexamethasone—multiple sclerosis	5.52e-05	0.00061	CcSEcCtD
Carvedilol—Oedema—Dexamethasone—multiple sclerosis	5.52e-05	0.00061	CcSEcCtD
Carvedilol—Diarrhoea—Mitoxantrone—multiple sclerosis	5.51e-05	0.00061	CcSEcCtD
Carvedilol—Insomnia—Triamcinolone—multiple sclerosis	5.5e-05	0.000608	CcSEcCtD
Carvedilol—Insomnia—Methylprednisolone—multiple sclerosis	5.49e-05	0.000607	CcSEcCtD
Carvedilol—Infection—Dexamethasone—multiple sclerosis	5.48e-05	0.000606	CcSEcCtD
Carvedilol—Infection—Betamethasone—multiple sclerosis	5.48e-05	0.000606	CcSEcCtD
Carvedilol—Ill-defined disorder—Prednisone—multiple sclerosis	5.46e-05	0.000604	CcSEcCtD
Carvedilol—Paraesthesia—Triamcinolone—multiple sclerosis	5.46e-05	0.000604	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisolone—multiple sclerosis	5.45e-05	0.000602	CcSEcCtD
Carvedilol—Paraesthesia—Methylprednisolone—multiple sclerosis	5.45e-05	0.000602	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—multiple sclerosis	5.45e-05	0.000602	CcSEcCtD
Carvedilol—Anaemia—Prednisone—multiple sclerosis	5.44e-05	0.000602	CcSEcCtD
Carvedilol—Shock—Betamethasone—multiple sclerosis	5.43e-05	0.0006	CcSEcCtD
Carvedilol—Shock—Dexamethasone—multiple sclerosis	5.43e-05	0.0006	CcSEcCtD
Carvedilol—Dyspnoea—Triamcinolone—multiple sclerosis	5.42e-05	0.000599	CcSEcCtD
Carvedilol—Thrombocytopenia—Dexamethasone—multiple sclerosis	5.4e-05	0.000597	CcSEcCtD
Carvedilol—Thrombocytopenia—Betamethasone—multiple sclerosis	5.4e-05	0.000597	CcSEcCtD
Carvedilol—Tachycardia—Dexamethasone—multiple sclerosis	5.38e-05	0.000595	CcSEcCtD
Carvedilol—Tachycardia—Betamethasone—multiple sclerosis	5.38e-05	0.000595	CcSEcCtD
Carvedilol—Angioedema—Prednisone—multiple sclerosis	5.38e-05	0.000595	CcSEcCtD
Carvedilol—Dyspepsia—Triamcinolone—multiple sclerosis	5.35e-05	0.000592	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—multiple sclerosis	5.34e-05	0.000591	CcSEcCtD
Carvedilol—Dyspepsia—Methylprednisolone—multiple sclerosis	5.34e-05	0.00059	CcSEcCtD
Carvedilol—Hyperhidrosis—Betamethasone—multiple sclerosis	5.33e-05	0.00059	CcSEcCtD
Carvedilol—Hyperhidrosis—Dexamethasone—multiple sclerosis	5.33e-05	0.00059	CcSEcCtD
Carvedilol—Malaise—Prednisone—multiple sclerosis	5.31e-05	0.000587	CcSEcCtD
Carvedilol—Vertigo—Prednisone—multiple sclerosis	5.29e-05	0.000585	CcSEcCtD
Carvedilol—Syncope—Prednisone—multiple sclerosis	5.28e-05	0.000584	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—multiple sclerosis	5.27e-05	0.000583	CcSEcCtD
Carvedilol—Anorexia—Betamethasone—multiple sclerosis	5.26e-05	0.000581	CcSEcCtD
Carvedilol—Anorexia—Dexamethasone—multiple sclerosis	5.26e-05	0.000581	CcSEcCtD
Carvedilol—Urticaria—Prednisolone—multiple sclerosis	5.25e-05	0.000581	CcSEcCtD
Carvedilol—Fatigue—Triamcinolone—multiple sclerosis	5.24e-05	0.00058	CcSEcCtD
Carvedilol—Fatigue—Methylprednisolone—multiple sclerosis	5.23e-05	0.000578	CcSEcCtD
Carvedilol—Pain—Triamcinolone—multiple sclerosis	5.2e-05	0.000575	CcSEcCtD
Carvedilol—ABCB1—brain—multiple sclerosis	5.18e-05	0.00123	CbGeAlD
Carvedilol—Loss of consciousness—Prednisone—multiple sclerosis	5.17e-05	0.000572	CcSEcCtD
Carvedilol—Hypotension—Betamethasone—multiple sclerosis	5.15e-05	0.00057	CcSEcCtD
Carvedilol—Hypotension—Dexamethasone—multiple sclerosis	5.15e-05	0.00057	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—multiple sclerosis	5.13e-05	0.000567	CcSEcCtD
Carvedilol—Vomiting—Mitoxantrone—multiple sclerosis	5.12e-05	0.000566	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—multiple sclerosis	5.1e-05	0.000564	CcSEcCtD
Carvedilol—Convulsion—Prednisone—multiple sclerosis	5.1e-05	0.000564	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—multiple sclerosis	5.09e-05	0.000563	CcSEcCtD
Carvedilol—Hypertension—Prednisone—multiple sclerosis	5.08e-05	0.000562	CcSEcCtD
Carvedilol—Rash—Mitoxantrone—multiple sclerosis	5.08e-05	0.000562	CcSEcCtD
Carvedilol—Dermatitis—Mitoxantrone—multiple sclerosis	5.08e-05	0.000561	CcSEcCtD
Carvedilol—Headache—Mitoxantrone—multiple sclerosis	5.05e-05	0.000558	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.03e-05	0.000556	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.03e-05	0.000556	CcSEcCtD
Carvedilol—Myalgia—Prednisone—multiple sclerosis	5.01e-05	0.000554	CcSEcCtD
Carvedilol—Arthralgia—Prednisone—multiple sclerosis	5.01e-05	0.000554	CcSEcCtD
Carvedilol—Feeling abnormal—Triamcinolone—multiple sclerosis	5.01e-05	0.000554	CcSEcCtD
Carvedilol—Feeling abnormal—Methylprednisolone—multiple sclerosis	5e-05	0.000553	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—multiple sclerosis	4.99e-05	0.000552	CcSEcCtD
Carvedilol—Insomnia—Betamethasone—multiple sclerosis	4.99e-05	0.000552	CcSEcCtD
Carvedilol—Insomnia—Dexamethasone—multiple sclerosis	4.99e-05	0.000552	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.98e-05	0.00055	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.96e-05	0.000548	CcSEcCtD
Carvedilol—Paraesthesia—Dexamethasone—multiple sclerosis	4.95e-05	0.000548	CcSEcCtD
Carvedilol—Paraesthesia—Betamethasone—multiple sclerosis	4.95e-05	0.000548	CcSEcCtD
Carvedilol—Discomfort—Prednisone—multiple sclerosis	4.95e-05	0.000547	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—multiple sclerosis	4.92e-05	0.000544	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisolone—multiple sclerosis	4.87e-05	0.000539	CcSEcCtD
Carvedilol—Dyspepsia—Dexamethasone—multiple sclerosis	4.86e-05	0.000537	CcSEcCtD
Carvedilol—Dyspepsia—Betamethasone—multiple sclerosis	4.86e-05	0.000537	CcSEcCtD
Carvedilol—Urticaria—Triamcinolone—multiple sclerosis	4.83e-05	0.000534	CcSEcCtD
Carvedilol—Urticaria—Methylprednisolone—multiple sclerosis	4.82e-05	0.000533	CcSEcCtD
Carvedilol—Body temperature increased—Triamcinolone—multiple sclerosis	4.81e-05	0.000531	CcSEcCtD
Carvedilol—Oedema—Prednisone—multiple sclerosis	4.8e-05	0.000531	CcSEcCtD
Carvedilol—Anaphylactic shock—Prednisone—multiple sclerosis	4.8e-05	0.000531	CcSEcCtD
Carvedilol—Abdominal pain—Methylprednisolone—multiple sclerosis	4.79e-05	0.00053	CcSEcCtD
Carvedilol—Decreased appetite—Dexamethasone—multiple sclerosis	4.79e-05	0.00053	CcSEcCtD
Carvedilol—Decreased appetite—Betamethasone—multiple sclerosis	4.79e-05	0.00053	CcSEcCtD
Carvedilol—Nausea—Mitoxantrone—multiple sclerosis	4.79e-05	0.000529	CcSEcCtD
Carvedilol—Infection—Prednisone—multiple sclerosis	4.77e-05	0.000528	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.76e-05	0.000527	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.76e-05	0.000527	CcSEcCtD
Carvedilol—Back pain—Methotrexate—multiple sclerosis	4.76e-05	0.000526	CcSEcCtD
Carvedilol—Fatigue—Dexamethasone—multiple sclerosis	4.76e-05	0.000526	CcSEcCtD
Carvedilol—Fatigue—Betamethasone—multiple sclerosis	4.76e-05	0.000526	CcSEcCtD
Carvedilol—Shock—Prednisone—multiple sclerosis	4.73e-05	0.000523	CcSEcCtD
Carvedilol—Pain—Betamethasone—multiple sclerosis	4.72e-05	0.000522	CcSEcCtD
Carvedilol—Pain—Dexamethasone—multiple sclerosis	4.72e-05	0.000522	CcSEcCtD
Carvedilol—Tachycardia—Prednisone—multiple sclerosis	4.69e-05	0.000518	CcSEcCtD
Carvedilol—Skin disorder—Prednisone—multiple sclerosis	4.67e-05	0.000516	CcSEcCtD
Carvedilol—Hyperhidrosis—Prednisone—multiple sclerosis	4.64e-05	0.000513	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—multiple sclerosis	4.64e-05	0.000513	CcSEcCtD
Carvedilol—Anorexia—Prednisone—multiple sclerosis	4.58e-05	0.000506	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—multiple sclerosis	4.56e-05	0.000505	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—multiple sclerosis	4.55e-05	0.000503	CcSEcCtD
Carvedilol—Feeling abnormal—Dexamethasone—multiple sclerosis	4.55e-05	0.000503	CcSEcCtD
Carvedilol—Feeling abnormal—Betamethasone—multiple sclerosis	4.55e-05	0.000503	CcSEcCtD
Carvedilol—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.51e-05	0.000499	CcSEcCtD
Carvedilol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.51e-05	0.000499	CcSEcCtD
Carvedilol—Hypersensitivity—Triamcinolone—multiple sclerosis	4.48e-05	0.000495	CcSEcCtD
Carvedilol—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.47e-05	0.000494	CcSEcCtD
Carvedilol—Malaise—Methotrexate—multiple sclerosis	4.44e-05	0.000491	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—multiple sclerosis	4.42e-05	0.000489	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—multiple sclerosis	4.4e-05	0.000487	CcSEcCtD
Carvedilol—Urticaria—Betamethasone—multiple sclerosis	4.38e-05	0.000485	CcSEcCtD
Carvedilol—Urticaria—Dexamethasone—multiple sclerosis	4.38e-05	0.000485	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.38e-05	0.000484	CcSEcCtD
Carvedilol—Dizziness—Prednisolone—multiple sclerosis	4.37e-05	0.000483	CcSEcCtD
Carvedilol—Asthenia—Triamcinolone—multiple sclerosis	4.36e-05	0.000482	CcSEcCtD
Carvedilol—Abdominal pain—Dexamethasone—multiple sclerosis	4.36e-05	0.000482	CcSEcCtD
Carvedilol—Body temperature increased—Betamethasone—multiple sclerosis	4.36e-05	0.000482	CcSEcCtD
Carvedilol—Abdominal pain—Betamethasone—multiple sclerosis	4.36e-05	0.000482	CcSEcCtD
Carvedilol—Body temperature increased—Dexamethasone—multiple sclerosis	4.36e-05	0.000482	CcSEcCtD
Carvedilol—Asthenia—Methylprednisolone—multiple sclerosis	4.35e-05	0.000481	CcSEcCtD
Carvedilol—Insomnia—Prednisone—multiple sclerosis	4.34e-05	0.00048	CcSEcCtD
Carvedilol—Paraesthesia—Prednisone—multiple sclerosis	4.31e-05	0.000477	CcSEcCtD
Carvedilol—Pruritus—Triamcinolone—multiple sclerosis	4.3e-05	0.000476	CcSEcCtD
Carvedilol—Cough—Methotrexate—multiple sclerosis	4.29e-05	0.000475	CcSEcCtD
Carvedilol—Pruritus—Methylprednisolone—multiple sclerosis	4.29e-05	0.000475	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—multiple sclerosis	4.26e-05	0.000471	CcSEcCtD
Carvedilol—Dyspepsia—Prednisone—multiple sclerosis	4.23e-05	0.000468	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—multiple sclerosis	4.19e-05	0.000463	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—multiple sclerosis	4.19e-05	0.000463	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—multiple sclerosis	4.19e-05	0.000463	CcSEcCtD
Carvedilol—Decreased appetite—Prednisone—multiple sclerosis	4.18e-05	0.000462	CcSEcCtD
Carvedilol—Rash—Prednisolone—multiple sclerosis	4.17e-05	0.000461	CcSEcCtD
Carvedilol—Dermatitis—Prednisolone—multiple sclerosis	4.16e-05	0.00046	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.16e-05	0.00046	CcSEcCtD
Carvedilol—Diarrhoea—Methylprednisolone—multiple sclerosis	4.15e-05	0.000459	CcSEcCtD
Carvedilol—Fatigue—Prednisone—multiple sclerosis	4.14e-05	0.000458	CcSEcCtD
Carvedilol—Headache—Prednisolone—multiple sclerosis	4.14e-05	0.000458	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—multiple sclerosis	4.14e-05	0.000458	CcSEcCtD
Carvedilol—Constipation—Prednisone—multiple sclerosis	4.11e-05	0.000454	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—multiple sclerosis	4.05e-05	0.000448	CcSEcCtD
Carvedilol—Dizziness—Triamcinolone—multiple sclerosis	4.02e-05	0.000445	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—multiple sclerosis	4.01e-05	0.000444	CcSEcCtD
Carvedilol—Dizziness—Methylprednisolone—multiple sclerosis	4.01e-05	0.000444	CcSEcCtD
Carvedilol—Infection—Methotrexate—multiple sclerosis	3.99e-05	0.000441	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisone—multiple sclerosis	3.96e-05	0.000438	CcSEcCtD
Carvedilol—Asthenia—Dexamethasone—multiple sclerosis	3.96e-05	0.000438	CcSEcCtD
Carvedilol—Asthenia—Betamethasone—multiple sclerosis	3.96e-05	0.000438	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—multiple sclerosis	3.93e-05	0.000435	CcSEcCtD
Carvedilol—Gastrointestinal pain—Prednisone—multiple sclerosis	3.93e-05	0.000434	CcSEcCtD
Carvedilol—Nausea—Prednisolone—multiple sclerosis	3.93e-05	0.000434	CcSEcCtD
Carvedilol—Pruritus—Dexamethasone—multiple sclerosis	3.9e-05	0.000432	CcSEcCtD
Carvedilol—Pruritus—Betamethasone—multiple sclerosis	3.9e-05	0.000432	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—multiple sclerosis	3.9e-05	0.000431	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—multiple sclerosis	3.88e-05	0.000429	CcSEcCtD
Carvedilol—Vomiting—Triamcinolone—multiple sclerosis	3.87e-05	0.000427	CcSEcCtD
Carvedilol—Vomiting—Methylprednisolone—multiple sclerosis	3.86e-05	0.000426	CcSEcCtD
Carvedilol—Rash—Triamcinolone—multiple sclerosis	3.83e-05	0.000424	CcSEcCtD
Carvedilol—Dermatitis—Triamcinolone—multiple sclerosis	3.83e-05	0.000423	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—multiple sclerosis	3.83e-05	0.000423	CcSEcCtD
Carvedilol—Rash—Methylprednisolone—multiple sclerosis	3.82e-05	0.000423	CcSEcCtD
Carvedilol—Dermatitis—Methylprednisolone—multiple sclerosis	3.82e-05	0.000423	CcSEcCtD
Carvedilol—Urticaria—Prednisone—multiple sclerosis	3.82e-05	0.000422	CcSEcCtD
Carvedilol—Headache—Triamcinolone—multiple sclerosis	3.81e-05	0.000421	CcSEcCtD
Carvedilol—Headache—Methylprednisolone—multiple sclerosis	3.8e-05	0.00042	CcSEcCtD
Carvedilol—Abdominal pain—Prednisone—multiple sclerosis	3.8e-05	0.00042	CcSEcCtD
Carvedilol—Body temperature increased—Prednisone—multiple sclerosis	3.8e-05	0.00042	CcSEcCtD
Carvedilol—Diarrhoea—Dexamethasone—multiple sclerosis	3.77e-05	0.000417	CcSEcCtD
Carvedilol—Diarrhoea—Betamethasone—multiple sclerosis	3.77e-05	0.000417	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—multiple sclerosis	3.75e-05	0.000415	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.66e-05	0.000404	CcSEcCtD
Carvedilol—Dizziness—Dexamethasone—multiple sclerosis	3.65e-05	0.000403	CcSEcCtD
Carvedilol—Dizziness—Betamethasone—multiple sclerosis	3.65e-05	0.000403	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—multiple sclerosis	3.63e-05	0.000401	CcSEcCtD
Carvedilol—Nausea—Triamcinolone—multiple sclerosis	3.61e-05	0.000399	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—multiple sclerosis	3.6e-05	0.000399	CcSEcCtD
Carvedilol—Nausea—Methylprednisolone—multiple sclerosis	3.6e-05	0.000398	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—multiple sclerosis	3.58e-05	0.000396	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—multiple sclerosis	3.57e-05	0.000395	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisone—multiple sclerosis	3.54e-05	0.000391	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—multiple sclerosis	3.53e-05	0.000391	CcSEcCtD
Carvedilol—Vomiting—Betamethasone—multiple sclerosis	3.51e-05	0.000388	CcSEcCtD
Carvedilol—Vomiting—Dexamethasone—multiple sclerosis	3.51e-05	0.000388	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—multiple sclerosis	3.49e-05	0.000386	CcSEcCtD
Carvedilol—Rash—Dexamethasone—multiple sclerosis	3.48e-05	0.000385	CcSEcCtD
Carvedilol—Rash—Betamethasone—multiple sclerosis	3.48e-05	0.000385	CcSEcCtD
Carvedilol—Dermatitis—Betamethasone—multiple sclerosis	3.47e-05	0.000384	CcSEcCtD
Carvedilol—Dermatitis—Dexamethasone—multiple sclerosis	3.47e-05	0.000384	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.47e-05	0.000383	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—multiple sclerosis	3.46e-05	0.000383	CcSEcCtD
Carvedilol—Headache—Dexamethasone—multiple sclerosis	3.46e-05	0.000382	CcSEcCtD
Carvedilol—Headache—Betamethasone—multiple sclerosis	3.46e-05	0.000382	CcSEcCtD
Carvedilol—Asthenia—Prednisone—multiple sclerosis	3.45e-05	0.000381	CcSEcCtD
Carvedilol—Pain—Methotrexate—multiple sclerosis	3.43e-05	0.00038	CcSEcCtD
Carvedilol—Pruritus—Prednisone—multiple sclerosis	3.4e-05	0.000376	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—multiple sclerosis	3.31e-05	0.000366	CcSEcCtD
Carvedilol—Diarrhoea—Prednisone—multiple sclerosis	3.29e-05	0.000363	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.28e-05	0.000363	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Methylprednisolone—multiple sclerosis	3.28e-05	0.0109	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Methylprednisolone—multiple sclerosis	3.28e-05	0.0109	CbGdCrCtD
Carvedilol—Nausea—Betamethasone—multiple sclerosis	3.28e-05	0.000362	CcSEcCtD
Carvedilol—Nausea—Dexamethasone—multiple sclerosis	3.28e-05	0.000362	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Dexamethasone—multiple sclerosis	3.22e-05	0.0107	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Betamethasone—multiple sclerosis	3.22e-05	0.0107	CbGdCrCtD
Carvedilol—Urticaria—Methotrexate—multiple sclerosis	3.19e-05	0.000353	CcSEcCtD
Carvedilol—Dizziness—Prednisone—multiple sclerosis	3.18e-05	0.000351	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—multiple sclerosis	3.17e-05	0.000351	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—multiple sclerosis	3.17e-05	0.000351	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Triamcinolone—multiple sclerosis	3.15e-05	0.0105	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Triamcinolone—multiple sclerosis	3.15e-05	0.0105	CbGdCrCtD
Carvedilol—Vomiting—Prednisone—multiple sclerosis	3.05e-05	0.000338	CcSEcCtD
Carvedilol—Rash—Prednisone—multiple sclerosis	3.03e-05	0.000335	CcSEcCtD
Carvedilol—Dermatitis—Prednisone—multiple sclerosis	3.03e-05	0.000335	CcSEcCtD
Carvedilol—Headache—Prednisone—multiple sclerosis	3.01e-05	0.000333	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Prednisone—multiple sclerosis	2.99e-05	0.00993	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Prednisone—multiple sclerosis	2.99e-05	0.00993	CbGdCrCtD
Carvedilol—Hypersensitivity—Methotrexate—multiple sclerosis	2.96e-05	0.000327	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Prednisolone—multiple sclerosis	2.92e-05	0.00969	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Prednisolone—multiple sclerosis	2.92e-05	0.00969	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Methylprednisolone—multiple sclerosis	2.89e-05	0.00959	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Methylprednisolone—multiple sclerosis	2.89e-05	0.00959	CbGdCrCtD
Carvedilol—Asthenia—Methotrexate—multiple sclerosis	2.88e-05	0.000318	CcSEcCtD
Carvedilol—Nausea—Prednisone—multiple sclerosis	2.85e-05	0.000316	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Betamethasone—multiple sclerosis	2.84e-05	0.00944	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Dexamethasone—multiple sclerosis	2.84e-05	0.00944	CbGdCrCtD
Carvedilol—Pruritus—Methotrexate—multiple sclerosis	2.84e-05	0.000314	CcSEcCtD
Carvedilol—VEGFA—Betamethasone—Triamcinolone—multiple sclerosis	2.78e-05	0.00922	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Triamcinolone—multiple sclerosis	2.78e-05	0.00922	CbGdCrCtD
Carvedilol—Diarrhoea—Methotrexate—multiple sclerosis	2.75e-05	0.000304	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—multiple sclerosis	2.65e-05	0.000294	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Prednisone—multiple sclerosis	2.64e-05	0.00875	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisone—multiple sclerosis	2.64e-05	0.00875	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisolone—multiple sclerosis	2.57e-05	0.00854	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Prednisolone—multiple sclerosis	2.57e-05	0.00854	CbGdCrCtD
Carvedilol—Vomiting—Methotrexate—multiple sclerosis	2.55e-05	0.000282	CcSEcCtD
Carvedilol—Rash—Methotrexate—multiple sclerosis	2.53e-05	0.00028	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—multiple sclerosis	2.53e-05	0.00028	CcSEcCtD
Carvedilol—Headache—Methotrexate—multiple sclerosis	2.51e-05	0.000278	CcSEcCtD
Carvedilol—Nausea—Methotrexate—multiple sclerosis	2.38e-05	0.000264	CcSEcCtD
Carvedilol—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	3.78e-06	4.32e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.78e-06	4.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—IL2—multiple sclerosis	3.76e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCL2—multiple sclerosis	3.76e-06	4.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	3.75e-06	4.28e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—BCHE—multiple sclerosis	3.75e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	3.74e-06	4.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL10—multiple sclerosis	3.74e-06	4.27e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TYK2—multiple sclerosis	3.73e-06	4.25e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TYK2—multiple sclerosis	3.72e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	3.72e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—TYK2—multiple sclerosis	3.71e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	3.69e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	3.66e-06	4.18e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SPP1—multiple sclerosis	3.59e-06	4.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CD86—multiple sclerosis	3.59e-06	4.1e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CD86—multiple sclerosis	3.56e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	3.53e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CD86—multiple sclerosis	3.51e-06	4.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL5—multiple sclerosis	3.5e-06	4e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCR5—multiple sclerosis	3.49e-06	3.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	3.49e-06	3.98e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—TYK2—multiple sclerosis	3.46e-06	3.95e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	3.46e-06	3.95e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2RA—multiple sclerosis	3.44e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	3.43e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	3.43e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2—multiple sclerosis	3.42e-06	3.9e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—TYK2—multiple sclerosis	3.41e-06	3.89e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	3.41e-06	3.89e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2—multiple sclerosis	3.4e-06	3.88e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	3.36e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	3.34e-06	3.81e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CD86—multiple sclerosis	3.32e-06	3.79e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	3.32e-06	3.79e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	3.27e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL5—multiple sclerosis	3.27e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CD86—multiple sclerosis	3.27e-06	3.73e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.25e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SPP1—multiple sclerosis	3.24e-06	3.7e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.23e-06	3.68e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL5—multiple sclerosis	3.22e-06	3.67e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.21e-06	3.67e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—APOE—multiple sclerosis	3.21e-06	3.66e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	3.2e-06	3.65e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—APOE—multiple sclerosis	3.2e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	3.18e-06	3.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	3.18e-06	3.63e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—APOE—multiple sclerosis	3.18e-06	3.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2—multiple sclerosis	3.17e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	3.17e-06	3.61e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCR5—multiple sclerosis	3.16e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	3.14e-06	3.58e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2—multiple sclerosis	3.12e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	3.12e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	3.12e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	3.11e-06	3.55e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2RA—multiple sclerosis	3.11e-06	3.55e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2—multiple sclerosis	3.1e-06	3.54e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	3.1e-06	3.54e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2—multiple sclerosis	3.09e-06	3.53e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	3.09e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2—multiple sclerosis	3.09e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—multiple sclerosis	3.08e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	3.07e-06	3.5e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	3.05e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	3.03e-06	3.46e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	3.03e-06	3.46e-05	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.01e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—BCHE—multiple sclerosis	2.99e-06	3.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SPP1—multiple sclerosis	2.98e-06	3.4e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.96e-06	3.38e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	2.95e-06	3.36e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—multiple sclerosis	2.93e-06	3.35e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—multiple sclerosis	2.93e-06	3.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	2.91e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	2.9e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCR5—multiple sclerosis	2.9e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—APOE—multiple sclerosis	2.9e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	2.88e-06	3.29e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CD80—multiple sclerosis	2.87e-06	3.28e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—APOE—multiple sclerosis	2.87e-06	3.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	2.86e-06	3.26e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2RA—multiple sclerosis	2.86e-06	3.26e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2—multiple sclerosis	2.84e-06	3.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—APOE—multiple sclerosis	2.83e-06	3.23e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—BCHE—multiple sclerosis	2.82e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	2.81e-06	3.21e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.8e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	2.78e-06	3.17e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.77e-06	3.17e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—POMC—multiple sclerosis	2.75e-06	3.14e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—POMC—multiple sclerosis	2.75e-06	3.14e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—POMC—multiple sclerosis	2.73e-06	3.12e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	2.7e-06	3.08e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	2.68e-06	3.06e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCL2—multiple sclerosis	2.67e-06	3.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	2.66e-06	3.03e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	2.65e-06	3.02e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—APOE—multiple sclerosis	2.64e-06	3.01e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CD80—multiple sclerosis	2.62e-06	2.99e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—MAPK1—multiple sclerosis	2.61e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—STAT3—multiple sclerosis	2.61e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—APOE—multiple sclerosis	2.6e-06	2.97e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STAT3—multiple sclerosis	2.6e-06	2.97e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CD80—multiple sclerosis	2.6e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	2.58e-06	2.94e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	2.58e-06	2.94e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CD80—multiple sclerosis	2.56e-06	2.92e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	2.54e-06	2.9e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.53e-06	2.89e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	2.52e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ALB—multiple sclerosis	2.51e-06	2.87e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ALB—multiple sclerosis	2.51e-06	2.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—POMC—multiple sclerosis	2.49e-06	2.84e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—POMC—multiple sclerosis	2.47e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	2.46e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	2.44e-06	2.78e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—POMC—multiple sclerosis	2.43e-06	2.78e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TYK2—multiple sclerosis	2.43e-06	2.77e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	2.42e-06	2.77e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MYC—multiple sclerosis	2.42e-06	2.77e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MYC—multiple sclerosis	2.42e-06	2.76e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TGFB1—multiple sclerosis	2.42e-06	2.76e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TGFB1—multiple sclerosis	2.41e-06	2.75e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL2—multiple sclerosis	2.41e-06	2.75e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	2.39e-06	2.73e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—APOE—multiple sclerosis	2.39e-06	2.73e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—BCHE—multiple sclerosis	2.39e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CD80—multiple sclerosis	2.39e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	2.38e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	2.38e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MAPK1—multiple sclerosis	2.37e-06	2.71e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MAPK1—multiple sclerosis	2.37e-06	2.7e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	2.36e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	2.36e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	2.34e-06	2.68e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	2.34e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	2.33e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	2.3e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	2.27e-06	2.59e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—APOE—multiple sclerosis	2.26e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	2.25e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—POMC—multiple sclerosis	2.24e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	2.22e-06	2.53e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	2.21e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	2.21e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	2.19e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	2.18e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	2.17e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	2.16e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	2.12e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—POMC—multiple sclerosis	2.05e-06	2.35e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	2.05e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ALB—multiple sclerosis	2.04e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—multiple sclerosis	2.02e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	2.01e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	2.01e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—multiple sclerosis	2.01e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	1.97e-06	2.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	1.97e-06	2.25e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—POMC—multiple sclerosis	1.94e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.93e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—multiple sclerosis	1.91e-06	2.18e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ALB—multiple sclerosis	1.87e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	1.87e-06	2.14e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.84e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—multiple sclerosis	1.84e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	1.83e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	1.83e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	1.82e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—multiple sclerosis	1.82e-06	2.08e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—multiple sclerosis	1.82e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	1.81e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—APOE—multiple sclerosis	1.8e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—multiple sclerosis	1.8e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.79e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	1.79e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	1.79e-06	2.04e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ALB—multiple sclerosis	1.77e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	1.74e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	1.73e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	1.7e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	1.7e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—multiple sclerosis	1.7e-06	1.94e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOE—multiple sclerosis	1.7e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	1.69e-06	1.93e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOE—multiple sclerosis	1.68e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	1.68e-06	1.91e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	1.67e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	1.66e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	1.61e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	1.59e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—multiple sclerosis	1.58e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—multiple sclerosis	1.58e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	1.55e-06	1.77e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—POMC—multiple sclerosis	1.55e-06	1.77e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK1—multiple sclerosis	1.54e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	1.53e-06	1.75e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	1.51e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	1.49e-06	1.7e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	1.48e-06	1.69e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—POMC—multiple sclerosis	1.46e-06	1.66e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—POMC—multiple sclerosis	1.45e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—multiple sclerosis	1.44e-06	1.64e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOE—multiple sclerosis	1.44e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	1.44e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	1.43e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	1.43e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	1.42e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—multiple sclerosis	1.41e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	1.41e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	1.41e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	1.41e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—multiple sclerosis	1.41e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	1.4e-06	1.6e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	1.39e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	1.38e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	1.38e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	1.38e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	1.33e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—multiple sclerosis	1.33e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	1.33e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—multiple sclerosis	1.32e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	1.31e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	1.31e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	1.31e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	1.3e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	1.28e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	1.25e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—POMC—multiple sclerosis	1.24e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—multiple sclerosis	1.19e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	1.16e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	1.16e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	1.16e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	1.14e-06	1.3e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—multiple sclerosis	1.13e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOE—multiple sclerosis	1.11e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	1.08e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—multiple sclerosis	1.08e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	1.08e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	1.07e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	1.06e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—multiple sclerosis	1.06e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	1e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	9.85e-07	1.12e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—POMC—multiple sclerosis	9.53e-07	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	8.75e-07	9.99e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—multiple sclerosis	8.69e-07	9.92e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	8.13e-07	9.28e-06	CbGpPWpGaD
